Shield Therapeutics PLC's (LON:STX) Tim Watts talks to Proactive London's Andrew Scott about the reanalysis of the AEGIS-H2H study for its lead product Feraccru. He says the study was intended to provide data comparing oral Feraccru /Accrufer against intravenous iron therapy, to allow economic data capture and analysis.
Shield Therapeutics CEO says reanalysis of key study has shown Feraccru to be 'credible alternative'
Quick facts: Shield Therapeutics PLC
Price: 35.5 GBX
Market Cap: £434.35 k
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE